Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial
RCT (n=380) found this whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel) showed better reactogenicity, safety outcomes and enhanced humoral and cell-mediated immune responses vs phase 1 data.
Source:
The Lancet Infectious Diseases